Clinical trials: Segment Elevation Myocardial Infarction (STEMI)
STEMI
Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction
Acute ST-segment elevation myocardial infarction (STEMI) is a common manifestation of cardiovascular emergencies. Percutaneous coronary intervention (PCI) and guideline-recommended pharmacotherapy have reduced mortality rates…
- Trial name
- NCT06364124
- Testing
- evolocumab, standard post-treatment for STEMI
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Beijing Luhe Hospital
ST Segment Elevation Myocardial Infarction
iFR-guided Revascularization in STEMI
Functional assessment of non-culprit lesions during percutaneous coronary intervention (PCI) in patients with acute coronary syndrome could improve risk stratification and long-term prognosis.
- Trial name
- WAVE (NCT03561389)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Azienda Ospedaliera San Camillo Forlanini
Myocardial Infarction
Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack
The study will evaluate the effect of BB3 to preserve myocardial (heart) tissue and function following myocardial infarction (heart attack).
- Trial name
- NCT01539590
- Testing
- BB3, Normal saline
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Angion Biomedica Corp
Acute Myocardial Infarction
Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction
The DEBATER study is designed to determine the superiority of abciximab over no abciximab and to determine the superiority of drug eluting stents over bare metal stents in patients with acute myocardial infarction who undergo…
- Trial name
- DEBATER (NCT00986050)
- Testing
- Abciximab, bare metal stent prokinetic, chrono, skylor or bluemedical, drug eluting stent (sirolimus eluting) - CYPHER stent
- Where
- Netherlands
- Volunteers
- 907 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
ST-segment Elevation Myocardial Infarction (STEMI)
Prolonged Clinical Follow-up of OPTIMA-5
The OPTIMA-5 trial is a prospective, multi-center, randomized, patient blinded, controlled trial comparing a single bolus of half-dose recombinant staphylokinase (r-SAK) with normal saline (NS) in patients with ST-segment…
- Trial name
- NCT05649696
- Testing
- Recombinant Staphylokinase, Normal Saline
- Where
- 8 sites in China
- Volunteers
- 210 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Acute Myocardial Infarction With ST Segment Elevation
3 Nehb Precordial Leads Anterior, Dorsalis and Inferior Allow Accurate Diagnostics of Different Heart Conditions
The method of ECG recording with the use of three bipolar leads A (anterior), D dorsalis) and J (or I - inferior) was introduced in 1938 by German electrophysiologist W. Nehb.
- Trial name
- Nehb-STEMI (NCT00623896)
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Assaf-Harofeh Medical Center
Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
EARLY-MYO-CMR-II Registry
The purpose of this registry is to depict the myocardial tissue characteristics in NSTEMI patients by CMR and other cardiac imaging modalities and to assess the prognostic value of imaging-derived indices.
- Trial name
- NCT03995433
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- RenJi Hospital
Left Ventricular Function Systolic Dysfunction, Left Ventricular Function Diastolic Dysfunction
Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI)
The purpose of this study is to investigate the efficacy and mechanism of bone marrow mononuclear cells (BMMNC) transplantation for diabetic and non-diabetic patients with ST-segment elevation myocardial infarction (STEMI)who…
- Conditions
- Left Ventricular Function Systolic Dysfunction, Left Ventricular Function Diastolic Dysfunction, Death, Myocardial Reperfusion Injury
- Trial name
- NCT01307371
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Xijing Hospital
Acute Anterior ST-Segment Elevation Myocardial Infarction
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of SGC001 injection administered in addition to…
- Trial name
- NCT07306182
- Testing
- SGC001 injection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Beijing Sungen Biomedical Technology Co., Ltd
Acute ST-segment Elevation Myocardial Infarction
Effects of Glucagon Like Peptide-1 on No-reflow
The investigators planned to evaluate the effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction (STEMI).
- Trial name
- NCT02507128
- Testing
- liraglutide
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Chen Wei Ren, MD
STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
Intensive Cholesterol-Lowering Within 24 Hours of PCI Perioperative Period
This project team is conducting a multicenter randomized controlled study, aiming to administer PCSK9 inhibitors subcutaneously as early as possible within 24 hours during the perioperative period of AMI (included <24h STEMI and…
- Trial name
- INCLINE-AMI (NCT07290699)
- Testing
- Recaticimab
- Volunteers
- 2,442 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Myocardial Infarction, Segment Elevation Myocardial Infarction (STEMI)
A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention…
- Trial name
- ATLANTIC (NCT01347580)
- Testing
- Ticagrelor
- Where
- 96 sites in Algeria, Australia and 11 more
- Volunteers
- 1,875 people
- Sponsor
- AstraZeneca
Myocardial Infarction, STEMI
Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)
Rationale: the use of antiplatelet drugs (i.e. clopidogrel, ticagrelor or prasugrel) is crucial in the treatment of patients undergoing percutaneous coronary intervention (PCI) with stent implantation to prevent atherothrombotic…
- Trial name
- NCT01761786
- Testing
- CYP2C19 genotyping
- Where
- 10 sites in Belgium, Italy and 1 more
- Volunteers
- 2,700 people
- Sponsor
- Vera HM Deneer
Atrial Fibrillation
The Incidence and Predictors of Developing Atrial Fibrillation in Patients With Inferior ST-segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention
Is to analyze the incidence and predictors of developing AF in patients with inferior infarction who undergo PCI with and without atrial and SN branches occlusion
- Trial name
- NCT03854448
- Testing
- holter monitoring
- Volunteers
- 109 people
- Sponsor
- Assiut University
Integrated Assessment, Immune-Inflammatory
Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients
This study aims to evaluate the combined predictive value of immune-inflammatory and metabolic biomarkers for coronary no-reflow following primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation…
- Conditions
- Integrated Assessment, Immune-Inflammatory, Metabolic Biomarkers, Coronary No-Reflow
- Trial name
- NCT07890168
- Testing
- Assessment of immune-inflammatory and metabolic biomarkers
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Sohag University
Myocardial Infarction, ST Segment Elevation Myocardial Infarction (STEMI)
A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study
This is a prospective randomized study, which investigates the coronary microvascular function as assessed by coronary angiography after administration of ticagrelor compared with clopidogrel in patients with myocardial…
- Trial name
- MIRTOS (NCT02429271)
- Testing
- Ticagrelor, Clopidogrel, Percutaneous Coronary Intervention (PCI)
- Where
- Greece
- Volunteers
- 336 people
- Sponsor
- Hellenic Cardiovascular Research Society
Acute Myocardial Infarction
Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty. The OCTAVIA Trial
Recent studies suggest important gender differences in the pathophysiology and prognosis of ST-segment elevation myocardial infarction (STEMI).
- Trial name
- OCTAVIA (NCT01377207)
- Testing
- Primary PCI
- Where
- 14 sites in Italy
- Volunteers
- 140 people
- Sponsor
- Italian Society of Invasive Cardiology
STEMI, Percutaneous Coronary Intervention
Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction
The study is an investigator-sponsored, prospective, multicenter, randomized, open-label study designed to compare efficacy and safety between bivalirudin and heparin in elderly patients with acute ST-segment elevation myocardial…
- Conditions
- STEMI, Percutaneous Coronary Intervention, Aged
- Trial name
- BEST (NCT03882775)
- Testing
- Bivalirudin, Heparin
- Where
- China
- Volunteers
- 240 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Non ST Segment Elevation Myocardial Infarction, Unstable Angina
Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation
This non-inferiority study aims at comparing Versa® to the reference enoxaparin (Clexane®, Sanofi-Aventis) in patients with high-risk unstable angina and NSTEMI.
- Trial name
- VECOR (NCT01356992)
- Testing
- Enoxaparin
- Where
- 5 sites in Brazil
- Volunteers
- 62 people
- Sponsor
- Eurofarma Laboratorios S.A.
Myocardial Infarction, Coronary Disease
Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome
The purpose of this study is to determine which of these anti-clotting medications, abciximab plus unfractionated heparin or bivalirudin, is more effective to prevent thrombotic and bleeding complications in patients suffering…
- Trial name
- ISAR-REACT-4 (NCT00373451)
- Testing
- Abciximab + UFH, Bivalirudin, Heparin
- Where
- 9 sites in Germany, Italy
- Volunteers
- 1,721 people
- Sponsor
- Deutsches Herzzentrum Muenchen